Department of Emergency Medicine, Gulhane Military Medical Academy, GATA Acil Tip Anabilim Dalı, Etlik, 06010 Ankara, Turkey.
Am J Emerg Med. 2012 Oct;30(8):1486-90. doi: 10.1016/j.ajem.2011.12.010. Epub 2012 Feb 4.
The aim of this study was to compare the efficacy and safety of 3 nonsteroidal anti-inflammatory drugs-intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol-for the treatment of patients with renal colic.
We conducted a prospective double-blind randomized trial of consecutive adult patients who presented to the emergency department with a chief complaint of acute flank pain and had a clinical diagnosis of suspected acute renal colic. Patients were randomly allocated to receive an intravenous bolus of tenoxicam, lornoxicam, or dexketoprofen trometamol in a blinded fashion. Primary outcome measure of the study was visual analog scale (VAS) score difference at 30 minutes. Secondary outcome measures were VAS scores at 5, 15, and 120 minutes as well as rescue analgesic need at 30 minutes and adverse events during the follow-up period.
A total of 445 patients were screened, and 123 patients were enrolled in the study. The mean age was 36 ± 10 years. The mean reduction in VAS pain scores at 30 minutes was 42 ± 26 mm for tenoxicam, 57 ± 23 mm for lornoxicam, and 52 ± 25 mm for dexketoprofen (P = .047). Lornoxicam demonstrated the fastest rate of VAS score reduction over the first 30 minutes. The mean reduction values in VAS pain scores at 5, 15, and 120 minutes were similar among the 3 groups. Rescue analgesics at 30 minutes were required by 16 patients (39%) receiving tenoxicam, 10 patients (24%) receiving lornoxicam, and 8 patients (19%) receiving dexketoprofen (P = .121). No serious adverse events were observed.
Intravenous tenoxicam, lornoxicam, and dexketoprofen are all effective in the treatment of renal colic, although lornoxicam appears to reduce VAS pain scores with the fastest rate in this comparison.
本研究旨在比较 3 种非甾体抗炎药(静脉注射替扎尼定、洛索洛芬和右旋酮洛芬)治疗肾绞痛患者的疗效和安全性。
我们进行了一项前瞻性、双盲、随机临床试验,纳入了因急性腰痛就诊于急诊科、临床诊断为疑似急性肾绞痛的成年患者。患者以盲法随机分配接受静脉推注替扎尼定、洛索洛芬或右旋酮洛芬。研究的主要结局测量指标为 30 分钟时视觉模拟评分(VAS)差值。次要结局测量指标为 5、15 和 120 分钟时的 VAS 评分以及 30 分钟时的解救性镇痛需求以及随访期间的不良事件。
共筛选了 445 例患者,其中 123 例患者入组研究。平均年龄为 36 ± 10 岁。替扎尼定组 30 分钟时 VAS 疼痛评分的平均降幅为 42 ± 26mm,洛索洛芬组为 57 ± 23mm,右旋酮洛芬组为 52 ± 25mm(P =.047)。洛索洛芬在最初 30 分钟内 VAS 评分降低的速度最快。3 组患者在 5、15 和 120 分钟时 VAS 疼痛评分的平均降幅值相似。接受替扎尼定的 16 例患者(39%)、接受洛索洛芬的 10 例患者(24%)和接受右旋酮洛芬的 8 例患者(19%)在 30 分钟时需要解救性镇痛(P =.121)。未观察到严重不良事件。
静脉注射替扎尼定、洛索洛芬和右旋酮洛芬均有效治疗肾绞痛,尽管洛索洛芬在本比较中似乎以最快的速度降低 VAS 疼痛评分。